Vitamin B2 (Riboflavin) for Migraine

Verdict: Probably effective for preventing migraine frequency

High-dose riboflavin (vitamin B2), typically 400 mg/day for at least three months, has preliminary evidence that it can modestly reduce how often adults get migraine attacks. It is not a painkiller for an attack in progress, and the benefit appears limited to attack frequency rather than how long or how severe each migraine is.

B 🟡 B Preliminary Evidence Published

🔬Why this grade7-layer evidence engine

This earns a B (preliminary evidence) grade because the supportive data are consistent but thin. The anchor is a small double-blind RCT (Schoenen 1998, PMID 9484373): 400 mg/day for three months left 59% of patients with at least a 50% drop in attack frequency versus 15% on placebo (p=0.005, NNT 2.3), and significantly fewer headache days (p=0.012), though attack severity did not change. An open-label study (Boehnke 2004, PMID 15257686) saw attacks fall from 4 to 2 per month, and two systematic reviews (Thompson 2017, PMID 28485121; Namazi 2015) found 9 of 11 studies positive in adults.

The grade does not climb higher because the evidence base is modest: the anchor trial was small, single-center and industry-funded, with no large independent RCT replicating it. A combination trial (Maizels 2004, PMID 15447697) is confounded by using low-dose riboflavin as its 'placebo,' so it cannot prove efficacy. Pediatric trials at 50-200 mg/day were inconclusive, so the benefit applies to adults at the full 400 mg dose.

Authorities are split, which keeps expectations measured. Cleveland Clinic and Harvard Health cautiously endorse it for prevention at 400 mg/day, but Mayo Clinic lists migraine as an unproven use. Regulators (EFSA, NHS) only recognize riboflavin's basic nutritional roles and have never approved a migraine treatment claim, with NHS noting limited evidence for high-dose use. Safety is excellent: the main effect is harmless bright-yellow urine.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published
Confidence
84%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.39
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.631
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial
PMID: 9484373 1998 隨機對照試驗 n = 55
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Riboflavin 400 mg/day for 3 months reduced migraine attack frequency and headache days significantly more than placebo; 59% of riboflavin patients improved by >=50% on attack frequency vs 15% on placebo (p=0.005); NNT for 50% responder = 2.3."}, "duration": {"direction": "reduction", "significant": true, "narrative": "Significant reduction in headache days/month vs placebo (p=0.012)."}, "severity": {"direction": "no_change", "significant": false, "narrative": "Headache severity (intensity) not significantly different."}}
⚠️ Industry-funded
View on PubMed
High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre
PMID: 15257686 2004 RCT (open-label) n = 23
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Mean monthly migraine attack frequency dropped from 4 to 2 (p<0.05); headache days fell from 6 to 3; abortive medication intake dropped from 7 to 4.5 units/month (all p<0.05). Open-label, no placebo control."}}
View on PubMed
A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial
PMID: 15447697 2004 隨機對照試驗 n = 49
Finding: {"frequency_per_month": {"direction": "reduction", "significant": false, "narrative": "Both arms improved (>=50% responder ~42% combo vs ~44% placebo arm with riboflavin 25 mg); the chosen 'placebo' of riboflavin 25 mg appeared itself active, undermining contrast. Often cited as evidence that even low-dose riboflavin (25 mg) may carry biologic effect, but trial cannot establish riboflavin efficacy as monotherapy."}}
⚠️ Industry-funded
View on PubMed
Prophylaxis of migraine headaches with riboflavin: A systematic review
PMID: 28485121 2017 系統性回顧 n = 251
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Across 11 included studies (5 RCTs, 6 open/observational), 9/11 reported significant benefit of riboflavin 400 mg/day on migraine frequency and headache days in adults; pediatric data inconsistent. Authors conclude riboflavin is a safe, well-tolerated, low-cost option supporting AAN/AHS Level B recommendation; effect on adult frequency consistent with Schoenen 1998 anchor result."}}
View on PubMed
Prophylaxis of migraine headaches with riboflavin: A systematic review
PMID: 28485121 2015 系統性回顧 n = 251
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Across 11 included studies (5 RCTs, 6 open/observational), 9/11 reported significant benefit of riboflavin 400 mg/day on migraine frequency and headache days in adults; pediatric data inconsistent. Authors conclude riboflavin is a safe, well-tolerated, low-cost option supporting AAN/AHS Level B recommendation; effect on adult frequency consistent with Schoenen 1998 anchor result."}}
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Supportive
a cause and effect relationship has been established between the dietary intake of riboflavin and (a) contribution to normal energy-yielding metabolism, (b) contribution to normal functioning of the nervous system, (c) maintenance of normal mucous membranes, (d) maintenance of normal red blood cells, (e) maintenance of normal skin, (f) maintenance of normal vision, (g) normal metabolism of iron… source↗
L4c UK NHS
Cautious
Riboflavin (vitamin B2) helps: keep skin, eyes and the nervous system healthy; the body release energy from food. ... Adults (aged 19 to 64) need about: 1.3mg a day of riboflavin for men; 1.1mg a day of riboflavin for women. You should be able to get all the riboflavin you need from your daily diet. Riboflavin cannot be stored in the body, so you need it in your diet every day. ... There's not … source↗
L4d TW TFDA / 衛福部
Supportive
維生素B2有助於維持能量正常代謝;維生素B2有助於維持皮膚的健康 source↗
L4e WHO
Supportive
Riboflavin (vitamin B2) is an essential water-soluble vitamin that functions as a coenzyme in numerous redox reactions. The recommended nutrient intake for adults is 1.3 mg/day for men and 1.1 mg/day for women. source↗
L5a NIH Office of Dietary Supplements
Supportive
L5b Mayo Clinic
Against
L5c Cleveland Clinic
Cautious
Riboflavin (vitamin B2) has been shown to reduce the frequency and duration of migraine attacks. source↗
L5d Harvard Health
Cautious
A Belgian study treated 55 migraine patients with B2 or placebo over three months. Those taking the vitamin had significantly fewer migraine attacks. The dose, 400 mg, was over 200 times the recommended daily allowance, but side effects were minimal. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-migraine-INT-vitamin-b2-001 繁體中文版 →